Boxshot ultimate 5 0 8 percent. Dec 15, 1965 8:37:26.471 am EST. Due to a Gemini Agena target vehicle (GATV) propulsion failure on 25 Oct, 1965 the mission was rescheduled. The Agena target vehicle Gemini Agena target vehicle GATV-5002 and TLV 5301 with which the Gemini-VI-A was to rendezvous and dock, failed to go into orbit. A launch attempt on Dec 12, 1965 failed because. 01-32011 Peabody Gemini 2 MCU™ Multiple Chemical Unit Assembly, Includes (1) 12.5' x 6.25' x 24' 12 Gallon Primary Tank and (2) 6.25' x 6.25' x 24' 6 Gallon Primary Tanks, Polyethylene Construction, Blue Color, Without PumpDeck™.
- < Previous
- Next >
Home > Aurora Residents and Fellows > Aurora Gastroenterology Fellows > 14 Airserver trial download.
Title
GEMINI 2 Study Group. Vedolizumab as induction and maintenance therapy for Crohn's disease
Gemini 2 6 14 Ft
Authors
Recommended Citation
Faculty, Aurora Gastroenterology; Sandborn, W.; Feagan, B.; Rutgeerts, P.; Hanauer, S.; Colombel, J.; Sands, B.; Lukas, M.; Fedorak, R.; Lee, S.; Bressler, B.; Fox, I.; Rosario, M.; Sankoh, S.; Xu, J.; Stephens, K.; Milch, C.; Parikh, A.; and Study Group, GEMINI 2, 'GEMINI 2 Study Group. Vedolizumab as induction and maintenance therapy for Crohn's disease' (2013). Aurora Gastroenterology Fellows. Keycue 9 2 – displays all menu shortcut commands key. 14.
https://institutionalrepository.aah.org/gastrofellows/14
Abstract
BACKGROUND: The efficacy of vedolizumab, an α4β7 integrin antibody, in Crohn's disease is unknown.METHODS: In an integrated study with separate induction and maintenance trials, we assessed intravenous vedolizumab therapy (300 mg) in adults with active Crohn's disease. In the induction trial, 368 patients were randomly assigned to receive vedolizumab or placebo at weeks 0 and 2 (cohort 1), and 747 patients received open-label vedolizumab at weeks 0 and 2 (cohort 2); disease status was assessed at week 6. In the maintenance trial, 461 patients who had had a response to vedolizumab were randomly assigned to receive placebo or vedolizumab every 8 or 4 weeks until week 52.RESULTS: At week 6, a total of 14.5% of the patients in cohort 1 who received vedolizumab and 6.8% who received placebo were in clinical remission (i.e., had a score on the Crohn's Disease Activity Index [CDAI] of ≤150, with scores ranging from 0 to approximately 600 and higher scores indicating greater disease activity) (P=0.02); a total of 31.4% and 25.7% of the patients, respectively, had a CDAI-100 response (≥100-point decrease in the CDAI score) (P=0.23). Among patients in cohorts 1 and 2 who had a response to induction therapy, 39.0% and 36.4% of those assigned to vedolizumab every 8 weeks and every 4 weeks, respectively, were in clinical remission at week 52, as compared with 21.6% assigned to placebo (P<0.001 and P=0.004 for the two vedolizumab groups, respectively, vs. placebo). Antibodies against vedolizumab developed in 4.0% of the patients. Nasopharyngitis occurred more frequently, and headache and abdominal pain less frequently, in patients receiving vedolizumab than in patients receiving placebo. Vedolizumab, as compared with placebo, was associated with a higher rate of serious adverse events (24.4% vs. 15.3%), infections (44.1% vs. 40.2%), and serious infections (5.5% vs. 3.0%).CONCLUSIONS: Vedolizumab-treated patients with active Crohn's disease were more likely than patients receiving placebo to have a remission, but not a CDAI-100 response, at week 6; patients with a response to induction therapy who continued to receive vedolizumab (rather than switching to placebo) were more likely to be in remission at week 52. Adverse events were more common with vedolizumab. (Funded by Millennium Pharmaceuticals; GEMINI 2 ClinicalTrials.gov number, NCT00783692.).Comment in Inhibition of leukocyte trafficking in inflammatory bowel disease. [N Engl J Med. 2013]
Document Type
Article
DOI
10.1056/NEJMoa1215739
DOWNLOADS
Gemini 2 6 14 Explained
Since October 11, 2017
Gemini 2 6 14 Esv
COinS